Third Rock’s Eleven pitches a $69M IPO to fuel its PhIII dry eye program

John Carroll A little less than four years after Third Rock and Flagship joined forces and investment cash to back the launch of Eleven Biotherapeutics, the protein engineering company ...

Takeda suffers a big blow to its diabetes pipeline with PhIII failure of TAK-875

John Carroll Takeda has suffered a major setback in its quest to fill the blockbuster gap left by last year's loss of patent protection for the diabetes drug Actos. The pharma company ...

Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer

Damian Garde Onconova Therapeutics' shares took a 16% beating Tuesday night after the company's top prospect, rigosertib, failed a Phase III trial in patients with pancreatic ...

Argos rakes in $17.5M more to wrap up PhIII for cancer drug

Damian Garde Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get ...

Daiichi’s a-fib drug aces PhIII, faces crowded market

Damian Garde Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety ...

Merck’s next-gen HPV vaccine looks good in PhIII, but sales may disappoint

John Carroll Merck believes it can win near-term approval for a new HPV vaccine that will do better than Gardasil in guarding women against the virus that causes cervical cancer. But ...

AstraZeneca launches PhIII lung cancer study in late-stage rebuilding effort

John Carroll A decade after obtaining the rights to the cancer drug selumetinib from Array Biopharma, the hungry pharma giant AstraZeneca is moving the MEK inhibitor into a late-stage ...

Billionaire-backed immatics bags $46M to wrap cancer vaccine PhIII

Damian Garde Armed with a promising data and the support of biotech billionaire Dietmar Hopp, Germany's immatics now has the cash to get its cancer vaccine past the goal line, closing ...

Alzheimer’s investigators launch big PhIII program for Lundbeck, Otsuka drug

John Carroll Lundbeck and its partners at Otsuka are embarking on a lengthy Phase III journey in search of solid evidence that their Alzheimer's drug Lu AE58054 in combination with ...

Gilead scores early PhIII success for idelalisib in chronic lymphocytic leukemia

John Carroll Just weeks after sending in an application to the FDA seeking approval to start marketing its PI3k-delta inhibitor idelalisib for non-Hodgkin's lymphoma, Gilead ($ ...

Alkermes hits key milestone on pivotal PhIII schizophrenia study

John Carroll Ireland's Alkermes has hit a key milestone in its quest to develop a long-acting version of Abilify for schizophrenia. The biotech, which has R&D operations in ...

PhIII antibiotic developer gets a new name, new CEO in makeover

John Carroll The New Haven, CT-based biotech Rib-X is undergoing a makeover. The biotech has a new name and is now being run by a new management team drawn in by a new lead investor. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS